CD84 is a specific target for acute myeloid leukemia CAR-T cell therapy
Martina Pigazzi, Silvia Merlini, Ambra Da Ros, Olivia Marini, Giovanni Faggin, Nicolò Fortuna, Raffaele Mattera, Barbara Buldini, Paolo Rizzardi, Soheil Meshinchi, Giuseppe Basso, Franco Locatelli, Alessandra Biffi · 2026
Read CD84 is a specific target for acute myeloid leukemia CAR-T cell therapy by Martina Pigazzi, Silvia Merlini, Ambra Da Ros, Olivia Marini, Giovanni Faggin, Nicolò Fortuna, Raffaele Mattera, Barbara Buldini, Paolo Rizzardi, Soheil Meshinchi, Giuseppe Basso, Franco Locatelli, Alessandra Biffi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13369472.txt.
Description
CAR-T cell therapy has reshaped blood cancer care, but acute myeloid leukemia lacks a target found on cancer cells and not on healthy ones. Pigazzi and co-authors identify CD84, a surface protein carried strongly by leukemia blasts, above all in relapsed disease, yet barely present on normal blood stem cells. They build CAR-T cells aimed at CD84 and test them in lab and animal models.
The cells killed leukemia lines and patient-derived tumors, even ones with low CD84 levels, and doubled survival in treated mice. Normal stem cells were spared and kept their ability to rebuild blood. The authors argue for clinical testing in hard-to-treat leukemia.
Catalog record
| CREATOR | Martina Pigazzi, Silvia Merlini, Ambra Da Ros, Olivia Marini, Giovanni Faggin, Nicolò Fortuna, Raffaele Mattera, Barbara Buldini, Paolo Rizzardi, Soheil Meshinchi, Giuseppe Basso, Franco Locatelli, Alessandra Biffi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 58 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |